Kisqali Approved by FDA to Treat HR+, Advanced Disease

Options
Moderators
Moderators Member Posts: 25,912

Kisqali Approved by FDA to Treat Hormone-Receptor-Positive Advanced-Stage Disease
March 15, 2017
Kisqali was approved by the FDA on March 13, 2017 to be used in combination with an aromatase inhibitor to treat advanced-stage or metastatic hormone-receptor-positive, HER2-negative breast cancer that hasn't been treated with hormonal therapy yet in postmenopausal women. Read more...

Categories